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Abstract
Background: Mesenchymal stromal cells (MSC) have important immunomodulatory effects that can be exploited in the
clinical setting, e.g. in patients suffering from graft-versus-host disease after allogeneic stem cell transplantation. In an
experimental animal model, cultures of rat T lymphocytes were stimulated in vitro either with the mitogen Concanavalin A
or with irradiated allogeneic cells in mixed lymphocyte reactions, the latter to simulate allo-immunogenic activation of
transplanted T cells in vivo. This study investigated the inhibitory effects of rat bone marrow-derived MSC subsequently
found to be infected with a common mycoplasma species (Mycoplasma hyorhinis) on T cell activation in vitro and
experimental graft-versus-host disease in vivo.
Principal Findings: We found that M. hyorhinis infection increased the anti-proliferative effect of MSC dramatically, as
measured by both radiometric and fluorimetric methods. Inhibition could not be explained solely by the well-known ability
of mycoplasmas to degrade tritiated thymidine, but likely was the result of rapid dissemination of M. hyorhinis in the
lymphocyte culture.
Conclusions: This study demonstrates the potent inhibitory effect exerted by M. hyorhinis in standard lymphocyte
proliferation assays in vitro. MSC are efficient vectors of mycoplasma infection, emphasizing the importance of monitoring
cell cultures for contamination.
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Introduction
Mesenchymal stromal cells (MSC) comprise a heterogeneous
populationof progenitor cellsthat candifferentiate alongmesodermal
lineages[1].Ascharacteristicmarkersare lacking,MSCare currently
defined by a set of minimal criteria based on their morphology,
phenotypeand multipotency [2]. Multipotent stromalprogenitor cells
were originally isolated from the bone marrow (BM) [3], but are
readily available from many adult and fetal tissues [4–7]. In recent
years, a number of studies have shown that MSC have important
immunomodulatory potential [8–12]. MSC can suppress the
activation and proliferation of T and B cells, inhibit proliferation
and cytotoxicity of NK cells, block the activation and maturation of
dendritic cells, and induce expansion of regulatory T cells [13].
Although a variety of soluble mediator molecules have been
implicated [14], the molecular mechanisms by which MSC exert
their immunomodulatory effects are presently not well understood.
Graft-versus-host disease (GvHD) is caused by activation of
donor T cells due to disparities of major histocompatibility
complex (MHC) and minor histocompatibility antigens with the
recipient. MSC have emerged as a promising treatment modality
for GvHD after allogeneic stem cell transplantation [15,16]. A
clinical phase II study showed that a majority of patients suffering
from acute, steroid-refractory GvHD responded to treatment with
one or several MSC transfusions [17]. This effect was independent
of the MHC constitution of the MSC donor. Conversely, results
from experimental animal models have been conflicting. While
some attempts to treat GvHD with MSC have been successful in
murine models of allogeneic BM transplantation (BMT) [18,19],
other studies have failed to show a protective effect [20–22]. The
influence of source of MSC, experimental protocols and treatment
strategies on the efficiency of MSC remain unclear.
Mycoplasmas are parasitic bacteria that lack a cell wall and
colonize animals and plants. In humans and other mammals, they
have been associated with a variety of maladies in the respiratory
tract and the genito-urinary tract. Interactions of mycoplasma with
the host immune system are currently not fully understood. Efforts
to prevent mycoplasma infection have proven difficult, partly due
PLoS ONE | www.plosone.org 1 January 2011 | Volume 6 | Issue 1 | e16005to the lack of successful vaccination strategies [23]. Several strains
of mycoplasma frequently occur as latent contaminants of human
and animal cell lines in research laboratories [24]. Mycoplasma
hyorhinis is a pathogen of the porcine respiratory system and one of
the most common cell culture contaminants [24]. Infections can
remain undetected unless methods such as polymerase chain
reaction (PCR) using mycoplasma-specific primer sequences are
employed. Recently, M. hyorhinis has been implicated in the
transformation of human prostate cells [25] and thus may pose a
significant health risk related to carcinogenesis.
The aim of this work was to evaluate the immunosuppressive
effects of rat MSC on mixed lymphocyte reactions (MLR) in vitro
and GvHD in vivo using an experimental animal model of MHC-
mismatched BMT. In the course of this work, we noted that our
MSC lines were unusually potent inhibitors of MLR in vitro and
discovered that this was caused by accidental contamination of the
primary MSC cultures with M. hyorhinis.
Results
Mycoplasma-infected MSC strongly inhibit MLR and
mitogen-induced T cell proliferation in vitro
A MSC line generated from the BM of PVG strain rats
(expressing the RT1
c MHC haplotype) exhibited a potent
inhibitory effect on lymphocyte proliferation in vitro (Figure 1).
Tenfold dilutions of MSC were added to a MLR of PVG.7B (RT1
c;
used interchangeably with PVG) lymph node cells (LNC) and
allogeneic irradiated BN (RT1
n) stimulator cells. Incorporation of
tritiated thymidine ([
3H]TTP) was inhibited at ratios up to 1 MSC
per 10 000 responder cells (10
24) (Figure 1A). MSC were equally
effectiveinhibitors ofproliferationinducedbyConcanavalinA (Con
A; data not shown). Irradiation of MSC (20 Gy) did not change
their inhibitory capacity (data not shown). MSC showed a marked
inhibitory effect when introduced at delayed time points during
MLR or mitogen-induced stimulation, but required at least 3 d of
co-incubation with the responder cells (Figure 1B and data not
shown).
MSC exerted a potent inhibitory effect in transwell co-cultures
with LNC using 0.4 mm pore size membranes (data not shown).
Addition of cell-free MSC culture medium also resulted in strong
inhibition of MLR, but this effect was reversed by filtering through
0.22 mm membranes or repeated centrifugation at 100 000 g
(Figure 2A,B). Inhibition was furthermore mediated by the pellet
fraction sedimented at 100 000 g, but reversed by heat-inactivation
for 30 min at 60uC (Figure 2B,C). These inhibitory effects were
striking compared with several previous reports of MSC from
different species [8,9,11,12,20,21], and it was therefore with some
disappointment that we discovered that the cells were infected with
M. hyorhinis, a common cell culture contaminant (cf. Materials and
Methods).
A single mycoplasma-infected MSC can inhibit allogeneic
MLR
A second MSC line derived from another MHC-congenic strain
on the PVG background (PVG.1U expressing the RT1
u MHC
haplotype), which was also subsequently found to be infected with
M. hyorhinis, displayed an even stronger inhibition of lymphocyte
proliferation (Figure 3). [
3H]TTP incorporation was fully
abrogated (less than 15% of the positive control) by addition of
only 2 MSC per 200 000 LNC responder cells (10
25) at the start of
the MLR culture. At even lower MSC:LNC ratios (10
26), we
observed an ‘‘all-or-none’’ phenomenon, with either full inhibition
or normal proliferation in individual wells. To evaluate whether
inhibition was mediated by single infected cells, we added serial
threefold dilutions in replicate wells as depicted schematically in
Figure 3A. Complete block of proliferation was observed in
mycoplasma-contaminated wells as detected by PCR, while
normal responses were recorded in mycoplasma-negative wells
(Figure 3B,C). Analogous results were obtained for MSC/LNC co-
cultures stimulated with Con A (data not shown). These data
Figure 1. Mycoplasma-infected MSC effectively inhibit MLR. (A) MSC generated from the BM of PVG rats, subsequently found to be infected
with M. hyorhinis, were added in tenfold dilutions at the start of co-cultures of 2610
5 PVG.7B LNC and 2610
5 irradiated BN LNC (gray bars). No MSC
were added to the positive control (MLR, black bar). The basal proliferation of PVG.7B LNC in the absence of stimulus is also shown as negative
control (neg ctrl, white bar). Values on the x-axis denote the common logarithm (log) of MSC:LNC ratios, i.e. 1:10 (21) through 1:100 000 (25). [
3H]TTP
incorporation was abrogated depending on the number of mycoplasma-infected MSC added. (B) MSC were added either at the start of MLR (dark
gray bars), after 24 h (light gray) or 48 h (white), respectively, at 1:100 (22) or 1:10 000 (24) MSC:LNC ratios, and co-cultured for a total of 4 d. No
MSC were added to the positive control (MLR). Mycoplasma-infected MSC fully inhibited the assay with at least 3 d of co-incubation at the 1:100
MSC:LNC ratio. Representative data from at least three independent experiments are shown as the mean plus the standard error of the mean of
triplicates. Statistical difference to the respective positive controls,N P,.05,NN P,.01.
doi:10.1371/journal.pone.0016005.g001
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on lymphocyte proliferation in vitro.
The suppressive effect of mycoplasma infection is
removed by anti-mycoplasma treatment and restored by
re-infection
The PVG.1U MSC line was treated with Mynox (cf. Materials
and Methods) to resolve the mycoplasma infection. As a result of
the treatment, the cells were consistently free from mycoplasma as
confirmed by PCR, and most of the observed inhibitory capacity
was concomitantly lost (Figure 4A). MLR stimulation was
prevented only at a relatively high MSC:LNC cell ratio of 1:10,
in line with several previous MSC studies [9,20,21]. Similar results
were obtained with Con A-induced proliferation (unpublished
observations). Intentional contamination of a previously uninfect-
ed MSC line with mycoplasma-containing supernatant increased
its suppressive potential dramatically (Figure 4B), showing the
same phenomenon of either full inhibition or a normal
proliferative response in individual wells at limiting dilutions.
Figure 2. MLR is inhibited by MSC culture supernatant.
Inhibition of lymphocyte proliferation was reversed either by (A)
filtration at 0.22 mm, (B) serial centrifugation at 100 000 g,o r( C) heat-
treatment at 60uC. (A) MSC-conditioned supernatant (MSC-sn; gray
bars) was added at 1:10 (v/v) dilution (22 mL added to 200 mL per well)
at the start of mitogenic stimulation of 2610
5 PVG.7B LNC with Con A
(positive control with no MSC-sn added, black bar). MSC-sn was added
either unfiltered or filtered with the indicated cut-off sizes. (B) MSC-sn
was sedimented with the indicated centrifugal forces and durations
(min) and added at 1:10 (v/v) dilution at the start of allogeneic MLR
(cf. Figure 1). The pellet fraction (MSC-pt) was obtained after
centrifugation twice for 60 min at 100 000 g, resuspended and added
at 1:10 (v/v) dilution to the MLR. (C) Unprocessed MSC-sn or the
resuspended pellet fraction described in panel B were treated at 30uC
(light gray bars) and 60uC (dark gray) for 30 min, respectively, before
adding to MLR (dilution 1:10). Representative data of at least two
independent experiments are shown as mean values plus the standard
error of the mean of quadruplicates. Statistical difference to the
respective positive controls,NN P,.01,NNN P,.001.
doi:10.1371/journal.pone.0016005.g002
Figure 3. A single mycoplasma-infected MSC can completely
block the MLR. (A) Mycoplasma-infected MSC were added at limiting
dilution conditions at the start of MLR cultures with 2610
5 responder
cells. Proliferation was assessed in 9 replicate wells for each dilution.
Wells with more than 70% or less than 15% of the [
3H]TTP incorporation
observed in the positive control (MLR without MSC) are shown as open
(#) and filled circles (N), respectively. The log of MSC:LNC ratios are
denoted. (B) Mycoplasma was detected in the supernatant of seven out
of nine wells at the 26.5 dilution shown in panel A, and in the same
wells (C) complete inhibition of MLR was observed. Positive (MLR) and
negative (neg ctrl) controls are also shown (mean of triplicates). Results
are representative of three independent experiments.
doi:10.1371/journal.pone.0016005.g003
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of a rat colon carcinoma (CC531s) cell line (Figure 4C). These data
were firm evidence that the strong inhibitory effect was mediated
by the contaminant and was not dependent on a specific cellular
vehicle.
M. hyorhinis effectively inhibits T cell proliferation as
evaluated by Carboxyfluorescein diacetate succinimidyl
ester (CFSE) dilution assay
Mycoplasmas are known to interfere with the read-out of
[
3H]TTP incorporation assays commonly used to measure DNA
synthesis during lymphocyte proliferation, due to their endogenous
pyrimidine-nucleosidase activity [26]. We therefore opted to use
the CFSE dilution assay as an alternative method to measure cell
division and cell proliferation [27]. Infected and mycoplasma-
treated MSC were added to Con A cultures of CFSE-labeled LNC
(Figure 5). The presence of mycoplasma-infected MSC led to
increased cell division arrest of both CD4
+ and CD8
+ T cells
compared to mycoplasma-free MSC. The levels of inhibition of
cell division correlated with [
3H]TTP incorporation of LNC
performed in parallel, and similar results were obtained for
allogeneic MLR (data not shown).
We also determined the relative numbers of natural T regulatory
(Treg) cellsin ourassays. Thefrequency of CD4
+CD25
hiFoxP3
+ Treg
cells markedly decreased as a result of addition of MSC to Con A
cultures (Figure S1A), indicating that inhibition was not mediated
by Treg cells. In line with this observation, cell death was increased
in mycoplasma-contaminated LNC cultures (Figure S1B). Taken
together, these data show that M. hyorhinis has a high capacity to
arrest lymphocyte proliferation in vitro. The extent to which M.
hyorhinis interfered with the [
3H]TTP incorporation assay by
substrate degradation is not known, however, the results from
CFSE dilution assays suggest that this effect is of less importance.
Mycoplasma is rapidly disseminated in lymphocyte
cultures
Because cultivation of M. hyorhinis in cell-free anaerobic agar
medium for microbiological assays is rarely feasible [24], we
performed semi-quantitative measurements of bacterial load by
PCR analysis of sequentially collected culture supernatants
(Figure 6). Initially, mycoplasma was detected only at high
MSC:LNC ratios, but bacterial titers increased more rapidly in
co-culture with LNC as compared to cultures of MSC alone, and
mycoplasma infection manifested even in the highest dilutions
where only single infected MSC were added to the MLR. Similar
results were obtained for PCR-testing of supernatants from Con A-
stimulated LNC co-cultures with MSC (data not shown).
Mycoplasma-infected MSC retain their cell phenotype,
differentiation potential and cytokine expression profile
in mixed lymphocyte cultures
Mycoplasma-contaminated MSC adhered to plastic surface in
vitro and had the cell morphology of spindle-shaped colony-
forming unit fibroblasts (Figure S2A). The infection did not seem
to inhibit in vitro growth or the differentiation potential of MSC
(Figure S2B,C,E-H and unpublished observations). MSC ex-
pressed surface markers CD59, CD71, CD90, and CXCR4, but
Figure 4. Mycoplasma-treated or previously uninfected MSC
show a markedly reduced ability to inhibit lymphocyte
proliferation. (A) Infected PVG.1U MSC were treated with Mynox
reagent to eradicate the mycoplasma infection. Tenfold dilutions of
untreated (dark gray bars) and treated MSC (light gray) were tested in
allogeneic MLR. Mycoplasma-treated MSC, which tested negative for
mycoplasma by PCR, inhibited MLR at 1:10 (21) but not at higher
dilutions. Mycoplasma-infected MSC, on the other hand, effectively
inhibited up to a cell ratio of 1:10
6 (26). Previously uninfected PVG.7B
MSC (B) or the rat colon carcinoma cell line CC531s (C) were
intentionally infected with M. hyorhinis by transfer of cell culture
supernatant from the infected PVG.1U MSC line shown in panel A.
Infection was verified by PCR after passage. MSC were added at the
start of MLR, and CC531s cells were irradiated to prevent spontaneous
proliferation and added at the start of lymphocyte culture with Con A.
Proliferation was effectively inhibited by addition of M. hyorhinis-
infected cells, but not by uninfected CC531s cells. Values on the x-axis
denote the log of MSC:LNC and CC531s:LNC ratios, respectively. When
infected cells were added at the highest dilutions, individual wells
showed either full inhibition or a normal proliferative response (cf.
Figure 3); e.g. when infected CC531s cells were added to the Con A
culture, proliferation was detected in one of three (log dilution 25) and
two of three (26) replicates. Representative data from at least three
independent experiments are shown as the mean plus the standard
error of the mean of (A, B) quadruplicates or (C) triplicates.
doi:10.1371/journal.pone.0016005.g004
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(RT1-A) were also expressed while class II MHC molecules (RT1-
B/D) were not detected by flow cytometric staining. Based on
these parameters, the cells are in accordance with the current
definition of MSC [2].
Culture supernatants from mycoplasma-positive MSC alone
contained considerable amounts of interleukin (IL)-6, but not other
cytokines tested (Figure S3A), in agreement with previous
observations of uninfected MSC [28]. Adding increasing numbers
of mycoplasma-positive MSC to MLR resulted in no significant
changes of the concentrations of IL-1b, IL-2 and IL-10. The levels
of IL-1a, IL-6, and granulocyte macrophage colony-stimulating
factor, however, were markedly increased, while IL-4, interferon-c
(IFNc) and tumor necrosis factor-a were clearly diminished after
6 d of co-incubation (Figure 7A and data not shown). These results
were in agreement with several previous observations on the effects
of murine and human MSC on cytokine secretion by stimulated
lymphocytes [29–31], but failed to reproduce an increase of IL-10
in co-cultures with human MSC [29,32].
Next, we studied the capacity of M. hyorhinis to suppress the
production of IFNc as an important function of activated T cells.
A significant fraction of T cells produce intracellular IFNc after
24 h of Con A stimulation (Figure 7B,C). Addition of mycoplas-
ma-infected MSC at ratios up to 1:1000 reduced the relative
frequency of IFNc
+ T cells. This effect can explain the
concentration-dependent decrease of IFNc observed in MLR/
MSC co-cultures (Figure 7A).
Blocking the IL-6 signal by addition of IL-6 specific antibody
did not counteract the suppressive effect of infected MSC. Also,
addition of recombinant IFNc, either alone or in combination
with anti-IL-6, was without effect (Figure S3B). These data suggest
that the changes in IL-6 or IFNc were not important for the
suppressive effect mediated by mycoplasma-infected MSC.
Intravenous injections of mycoplasma-positive MSC fail
to reduce GvHD severity in BM-transplanted rats
In a model of experimental allogeneic BMT, we used the same
combination of PVG.7B donor rats and fully MHC-mismatched
BN recipient rats as for MLR in vitro experiments. Lethally
irradiated (9.0 Gy total body irradiation) BN rats were injected
with 30610
6 T cell-depleted PVG.7B BM cells. Two weeks later,
at a time point when the transplanted recipients had regained their
initial body weight, donor lymphocyte infusions (DLI) of graded
minimal doses of 1.5–2.5610
6 CD3
+ T cells from PVG.7B lymph
node donors reproducibly invoked lethal GvHD in 90% of the
recipients. Two groups were treated with intravenous injections of
high doses of MSC that later proved to be infected with M.
hyorhinis.
Transplanted rats received either single or repeated injections of
1610
6 MSC 14 d after DLI before or after rats had developed
symptoms of ongoing acute GvHD, but with no improvements of
GvHD morbidity and mortality. All recipients were moribund
between 14 and 26 d after DLI regardless of either repeated
prophylactic (36MSC) or acutely curative (16MSC) cell therapy
(for details refer to Figure S4).
Discussion
We here report a potent inhibitory effect of M. hyorhinis infection
of MSC on in vitro lymphocyte proliferation assays based on
[
3H]TTP incorporation and CFSE dilution. Addition of single
infected MSC led to rapid dissemination of mycoplasma in mixed
lymphocyte cultures. Mycoplasma spp. have been shown to reach
titers in cell cultures sufficient to degrade pyrimidine substrates with
more than 90% efficiency within 3–5 d [34]. In our study, high
titers of mycoplasma were reached already after 2 d which may
explain the observed potent inhibition of lymphocyte proliferation
as a result of direct cytopathic/cytolytic effects. Studies testing for
proliferative responses should therefore rigorously control their cell
cultures for mycoplasma contamination.
Many mycoplasma strains, including M. hyorhinis, produce
nucleoside phosphorylases which rapidly convert [
3H]TTP to its
thymine-derivative in vitro [26,35]. Caution has therefore been
advised in the interpretation of in vitro proliferation assays based on
quantification of such compounds [26,34]. Due to its potent
enzymatic activity, it has been suggested that [
3H]TTP degradation
can be utilized as a sensitive detection method for mycoplasma
infection [36], however, specific PCR and other readily available
Figure 5. Mycoplasma-infected MSC inhibit T lymphocyte proliferation in vitro as measured by CFSE dilution. Previously uninfected
(light gray histograms) and intentionally infected PVG.7B MSC (dark gray; cf. Figure 4B) were added to CFSE-labeled, Con A-stimulated PVG.7B LNC
(values to the left denote the log of MSC:LNC ratios). LNC alone were cultured either with (black histogram) or without (white) Con A as positive and
negative controls, respectively. CFSE dilution indicating cell divisions was measured by flow cytometry after 3 d of incubation. Histogram plots
(percent of maximum count) are representative of triplicates and show the fluorescence intensity of lymphocyte populations gated on
CD3
+CD4
+CD8
2 (CD4 T cells) and CD3
+CD4
2CD8
+ (CD8 T cells). The potent inhibition of lymphocyte proliferation by infected MSC measured by CFSE
dilution cannot be explained by degradation of [
3H]TTP. For the highest dilution (26) of mycoplasma-infected MSC, individual cultures displayed
either full inhibition or full proliferation (cf. Figure 3); one replicate in which full lymphocyte proliferation was detected is shown. Data are
representative of three independent experiments.
doi:10.1371/journal.pone.0016005.g005
Figure 6. Mycoplasma infection spreads rapidly in MLR cultures. Mycoplasma-positive MSC were cultured either alone (right panel) or
together with PVG responder cells and irradiated BN cells (left panel) for 3 d. Supernatants were collected at the indicated time points and tested by
PCR. The log dilutions of MSC are denoted; ctrl, no MSC added. Mycoplasma was detectable at considerably lower MSC concentrations when co-
cultured with lymphocytes.
doi:10.1371/journal.pone.0016005.g006
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relatively low cost. We did not directly assess to which extent our
results reflect degradation of pyrimidine substrate, but this
mechanism could not explain the observed effect as proliferation
was similarly inhibited when measured by CFSE dilution.
These experiments also showed that proliferation of both CD4
+
and CD8
+ T cells was equally abrogated, and were in agreement
with the finding that ovine Con A-activated lymphoblast cultures
were inhibited by a different mycoplasma species (M. ovipneumoniae)
in a recent study [37]. CD4
+ T cells are critically involved in
clearing persisting bacterial infection. We speculate that the ability
to directly infect proliferating T lymphocytes inducing cell cycle
arrest and cell death can be an important mechanism for
mycoplasmas to evade and counteract an immune response.
Other plausible mechanisms such as inhibition through mycoplas-
ma membrane proteins have been suggested [38,39].
The inhibitory properties of rat MSC were dramatically
reduced by removal of M. hyorhinis by anti-mycoplasma treatment.
Mycoplasma-negative MSC had a weaker, but significant
inhibitory effect on T cell proliferation. Their suppressive potential
is in agreement with several previous findings where MSC
inhibition of responder cells were measured at ratios of 1:1 to
1:100 [8,9,11,12,20,21], while some studies have reported
exceptionally high immunosuppressive potential of MSC
[10,40,41].
In contrast to their substantial suppressive effects on lympho-
cytes in vitro, mycoplasma-infected MSC did not have a beneficial
effect upon preemptive or curative treatment of BM-transplanted
rats suffering from acute GvHD. The applied dosage of
1–2610
6 MSC (approximately 4–10610
6 per kg body weight) is
comparable to what is typically administered in patients [16,17].
Increasing the dose above 2610
6 MSC per injection was
associated with a high risk of pulmonary embolism and sudden
death of the animals (unpublished observations). Injected MSC
may be susceptible to immune responses in the host against
mycoplasma infection, which could explain their lack of efficiency
in alleviating GvHD. We cannot rule out, however, that the MSC
lines applied in the present study are ineffective in suppressing
alloreactive donor lymphocytes in vivo, as has been reported for
other animal studies [20–22,42]. The extent to which M. hyorhinis
infection can affect the inhibitory properties of MSC in vivo is
therefore not clear.
In our hands, mycoplasma infection did not deprive MSC of
their characteristic differentiation potential, nor their capacity to
proliferate or to secrete cytokines. Infection did not result in an
upregulation of class I or class II MHC surface expression. Thus,
M. hyorhinis infection of MSC may pass unnoticed. The host-
pathogen relationship between M. hyorhinis and MSC remains
elusive. The two important pro-inflammatory cytokines IFNc and
tumor necrosis factor-a were strongly reduced by the addition of
infected MSC to mixed lymphocyte cultures [29–31]. It is
conceivable that M. hyorhinis can alter the inherent immunosup-
pressive potential of MSC [43], e.g. by changing the expression of
cytokines and other important secreted proteins [44,45]. In order
Figure 7. Mycoplasma-infected MSC alter the cytokine profile of MLR and inhibit IFNc production by T cells. (A) Mycoplasma-positive
MSC (PVG) were added at the start of MLR of PVG.7B and irradiated BN LNC (1610
6 cells each) at the indicated dilutions (log [MSC:LNC]). The
concentration of various cytokines was determined in the supernatant at the end of 6 d co-culture. IL-6 was markedly increased, while interferon-c
(IFNc) and tumor necrosis factor-a (TNFa) were reduced by addition of MSC compared to the control MLR. Representative data from three
independent experiments are shown as the average of duplicates. (B) Mycoplasma-infected MSC (PVG.7B) were added at the start of Con
A-stimulated culture of PVG.7B LNC at the indicated tenfold dilutions. The fraction of IFNc-expressing CD3
+ T cells was determined after 24 h by
intracellular staining (triplicates were pooled) and flow cytometry, as shown in (C). Cells were gated on CD3
+ lymphocytes, numbers represent the
percentage of gated cells. Data are representative of three independent experiments.
doi:10.1371/journal.pone.0016005.g007
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understanding of the immunomodulatory properties of BM
stromal progenitor cells as well as the pathobiology of mycoplasma
infection on MSC and immune cells. This research may have
important implications for the design of vaccination strategies
against mycoplasma species which continue to cause disease
requiring extensive use of antibiotics in veterinary and human
medicine.
Materials and Methods
Ethics statement
Our Department of Comparative Medicine at the Institute of
Basic Medical Sciences led by our institutional veterinarian has
established the rules for feeding, monitoring and handling of
laboratory animals in compliance with regulations set by the
Ministry of Agriculture of Norway. The institutional veterinarian
has delegated authority from the Norwegian Animal Research
Authority (NARA) and approved the protocols (license numbers:
VIT02.02, VIT09.1512, 05.07), which were conducted in
compliance with ‘‘The Norwegian Regulations on Animal
Experimentation’’ and ‘‘The European Convention for the
Protection of Vertebrate Animals used for Experimental and
other Scientific Purposes’’. Intravenous injections were performed
under neuroleptanalgesia with fentanyl citrate and fluanisone
(HypnormH; VetaPharma, UK). All animals used in this study
were euthanized with CO2, and every effort was made to minimize
their suffering.
Animals
The PVG-RT7
b (PVG.7B) strain expresses an allotype of rat
CD45 (RT7.2) and was used interchangeably with the standard
PVG strain (RT7.1) as both strains express the RT1
c haplotype of
the rat MHC. PVG.7B and PVG-RT1
u (PVG.1U; RT1
u) rats were
bred at the Institute of Basic Medical Sciences, University of Oslo.
PVG and BN (RT1
n) rats were purchased from Harlan, The
Netherlands. The animals were housed on location under a
12:12 h light/dark cycle with access to food and filtered drinking
water ad libitum, and were routinely screened for common
pathogens following FELASA recommendations [46].
MSC isolation, ex vivo culture and differentiation assays
MSC lines were obtained from 8–11 w-old PVG, PVG.7B and
PVG.1U strain rats as previously described [47]. In short, BM cells
were aspirated from femurs and tibias, filtered through nylon cell
strainers (70 mm mesh; BD Biosciences, MA), and cultured in
MSC medium comprising a-modified minimal essential medium
supplemented with 20% fetal bovine serum and 100 U mL
21
penicillin, 100 mgm L
21 streptomycin, 250 ng mL
21 amphotericin
B (all from Invitrogen, UK) and 2 mM L-glutamine (Millipore,
MA) in 175 cm
2 culture flasks (Nunc, Denmark) at 37uCi na
humidified atmosphere of 5% CO2. Non-adherent cells were
removed after approximately 24 h by replacement of the MSC
medium. Adherent cells were allowed to expand to near
confluence, detached using 500 mgm L
21 trypsin and 200 mg
mL
21 EDTAN4Na (Invitrogen) and reseeded at a density of
approximately 500 cells per cm
2. Cells were used in experiments
after the third passage.
The differentiation potential of MSC was tested using
adipogenic and osteogenic assays. MSC were cultured for 3 w in
MSC medium supplemented with adipogenic (StemCell Technol-
ogies, BC) or osteogenic (10 nM dexamethasone, 50 mgm L
21
ascorbic acid, and 5 mM b-glycerophosphate; StemCell Technol-
ogies) stimulatory supplements. Neutral lipids in fat vacuoles were
visualized by staining with Oil Red O (Sigma Aldrich, CO) and
mineralization by staining with 40 mM Alizarin Red (Sigma
Aldrich).
Mycoplasma detection, treatment and infection
Supernatants from confluent cultures were tested for mycoplas-
mas by nested PCR [48] using the following primer sequences:
Mike-O-Plasma-F1 59-ACACCATGGGAGCTGCTAAT-39;M i k e
-O-Plasma-R1 59-CTTCWTCGACTTYCAGACCCAAGGCAT-
39; Mike-O-Plasma-F2 59-GTTCTTTGAAAACTGAAT-39;M i k e -
O-Plasma-R259-GCATCCACCAWAWACTCT-39.Mycoplasma-
positive PCR test results were confirmed using a detection kit
(MycoAlertH; Lonza Rockland, ME) based on enzymatic ATP-
conversion combined with luminescence measurement. MSC that
tested positive for mycoplasma were cultured in a quarantine
laboratory using MSC medium without antibiotics.
The mycoplasma strain was detected and identified as M.
hyorhinis from cell cultures by means of 16S ribosomal DNA PCR
and sequencing. DNA extracted from the cell cultures was
amplified and sequenced (ABI Prism 3730 DNA analyzer; Applied
Biosystems, CA) using two primers within the 16S rRNA gene.
The obtained sequences were compared to sequences in the NCBI
database using BLAST version 2.210.
In some experiments, non-infected MSC lines (PVG.1U or
PVG.7B) and a rat colon carcinoma cell line (CC531s, a kind gift
from Peter Kuppen, Leiden, The Netherlands) were deliberately
infected with M. hyorhinis by transferring membrane-filtered
(0.45 mm Filtropur S; Sarstedt, Germany) culture supernatant
from nearly confluent cultures of mycoplasma-positive MSC and
incubated for 1–2 d before replacement of fresh culture medium.
Infected cells were confirmed as mycoplasma-positive by PCR.
CC531s cells were maintained in culture medium comprising
Dulbecco’s modified Eagle’s medium (Invitrogen) supplemented
with 20% fetal bovine serum (Invitrogen) without antibiotics in a
quarantine laboratory. In another experiment, the original
infected MSC line was cleared of mycoplasma using MynoxH
reagent (Minerva Biolabs, Germany) according to the manufac-
turer’s protocol, and was confirmed negative by PCR. The treated
cell line continued to grow normally and no recurrence of
mycoplasma was observed in several passages after the treatment.
Mixed lymphocyte cultures and radionucleotide
incorporation assays
Mononuclear cells from mesenteric and cervical lymph nodes of
8–14 w-old PVG, PVG.7B and BN rats were obtained by filtering
through nylon cell strainers (BD Biosciences) and density gradient
centrifugation (Lymphoprep
TM; Medinor, Norway) following the
manufacturer’s protocol. Stimulator cells were irradiated with a
dose of 20.0 Gy using a
137Cs source (GammacellH 3000; MDS
Nordion, Canada). MLR were performed in RPMI medium 1640
supplemented with 10% heat-inactivated fetal bovine serum,
100 U mL
21 penicillin, 100 mgm L
21 streptomycin, 2 mM L-
glutamine and 25 mM 2-mercaptoethanol (MLR medium; all from
Invitrogen) with responder (PVG or PVG.7B) and stimulator cells
(BN; each 2610
5 unless otherwise specified) in 200 mL per well
using round-bottom, 96-well cell culture clusters (Corning, NY). In
the same format, Con A (Sigma Aldrich, MO) was used at a final
concentration of 5 mgm L
21 for mitogenic stimulation of
responder cells. Polyclonal rabbit anti-rat IL-6 antibody (Pepro-
Tech, UK) at 2 mgm L
21 or recombinant rat IFNc at 500 U
mL
21 was added where specified.
CC531s and MSC were harvested using trypsin and EDTA
(Invitrogen), washed twice, diluted in MLR medium, and in some
experiments irradiated (20 Gy) to inhibit mitosis, before adding to
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were removed from MSC cultures prior to cell harvest and
sedimented at 400 g for 10 min before adding to MLR cultures at
the indicated dilutions. They were further processed using syringe
filter units (Millipore, Ireland) of different mesh size (indicated) or
serial sedimentation applying increasing centrifugal force and
durations (indicated). The pellet fraction of 100 000 g sedimen-
tation (Optima
TM LE-80K Ultracentrifuge; Beckman Coulter
Inc., CA) was resuspended in a volume of MLR medium equal to
the original amount of supernatant.
DNA synthesis was assessed after 3 d of mitogen stimulation or
4 d of mixed lymphocyte culture by pulsing with 1 mCi of [
3H]TTP
(diluted in 20 mL MLR medium; Hartmann Analytic, Germany)
18–20 h before the termination of the culture. Cells were then
harvested on glass fiber filters using a cell harvester (Filtermate 196;
Packard Bioscience Co., CT) and radioactivity was measured with
MicroScint
TM O solution (PerkinElmer, MA) using a Top CountH
NXT
TM (Packard Bioscience) or Wallac 1450 MicroBetaH TriLux
(PerkinElmer) microplate scintillation counter.
CFSE dilution assays
In some experiments, responder cells were stained with CFSE
(Sigma Aldrich) prior to invitroculture.Briefly,cells wereresuspended
in OPTI-MEM (Invitrogen) at a concentration of 2610
6 mL
21 and
incubated with 500 nM CFSE for 10 min at 37uC before adding
MLR medium. The cells were then washed in MLR medium twice,
incubated for 5 min at 37uC,washed again and resuspended inMLR
medium. At the termination of MLR and Con A cultures, cells were
harvested and washed in phosphate buffered saline before labeling
with monoclonal antibodies (mAb) and flow cytometric analysis.
Intracellular staining and flow cytometry
The following mouse anti-rat mAb (conjugated in our own lab
unless stated otherwise; W3/25 and OX antibodies were a kind
gift from A. Neil Barclay, Oxford, UK) were used for flow
cytometric analysis: FITC-conjugated W3/25 (anti-CD4), PE-
conjugated G4.18 (anti-CD3; BD Biosciences), Alexa FluorH 647-
conjugated OX-38 (anti-CD4), biotin-conjugated OX-8 (anti-
CD8) or OX-39 (anti-CD25) followed by secondary staining with
PerCP-conjugated Streptavidin (BD Biosciences). In some exper-
iments, 50 mM propidium iodide (Sigma Aldrich) was added to
stained cells before analysis.
For intracellular FoxP3 staining, stimulated LNC were
harvested after 3 d of culture, stained with mAb, fixed with
fixation/permeabilization buffers (eBioscience, CA) and stained
with APC-conjugated rat anti-mouse/rat FJK-16s mAb (anti-
FoxP3; eBioscience) according to the manufacturer’s guidelines.
For intracellular IFNc staining, LNC were stimulated with Con A
(5 mgm L
21; Sigma Aldrich) for 24 h, and Brefeldin A (10 mg
mL
21; Sigma Aldrich) was added 4 h before termination of the
culture. Triplicate wells were pooled and cells stained with FITC-
conjugated G4.18 (anti-CD3; BD Biosciences), fixed with 4%
paraformaldehyde, permeabilized with 0.5% saponin, and stained
with PE-conjugated mouse anti-rat IFNc mAb (BD Biosciences).
For phenotypic characterization of MSC, cells were labeled with
the followingconjugated mouse anti-ratmAb: PE-conjugated TLD-
3A12 (anti-CD31) or OX-7 (anti-CD90); FITC-conjugated TH9
(anti-CD59); PE-Cy5 conjugated OX-1 (anti-CD45; all from BD
Biosciences). For two-step immunostaining, cells were first incubat-
ed with supernatant of OX-26 (anti-CD71), or purified OX-18
(anti-RT1-A, pan-MHC class I) or OX-6 (anti-RT1-B/D, pan-
MHC class II; all our own), followed by secondary PE-conjugated
donkey anti-mouse IgG (Jackson ImmunoResearch, UK); or with
TP-503 (polyclonal rabbit anti-rat CXCR4; Torrey Pines Biolabs,
NJ) followed by secondary FITC-conjugated anti-rabbit IgG (BD
Biosciences). PE-conjugated mouse IgG1 (BD Biosciences) and
FITC-conjugated mouse IgG2a (DAKO, Denmark) were used as
isotype controls. Cells were analyzed on a FACSCalibur
TM or
FACSCanto
TMflowcytometer (BD Biosciences)using CellQuest
TM
software (BD Biosciences). FACS data were further analyzed using
FlowJo
TM software (TreeStar Inc., OR).
Cytokine assays
For cytokine measurements, 10610
6 responder and 10610
6
stimulator cells were co-cultured for 6–7 d in MLR medium
together with specified numbers of MSC in upright 25 cm
2 culture
flasks (Nunc). Cytokine levels were analyzed using the Bio-Plex
TM
Rat Cytokine 9-Plex A Panel (Bio-Rad, CA) according to the
manufacturer’s protocol. Concentrations were determined on the
basis of a standard curve using defined reference samples which
were assayed (Luminex xMAPH Technology; Bio-Rad) in parallel.
Experimental BMT and GvHD monitoring
Allogeneic stem cell transplantations were adapted from a
previously described protocol [49]. BM cells were aspirated from
femursandtibiasof8-12w-oldmaleandfemalePVG.7Brats,filtered
through cell strainers (BD Biosciences) and purified by density
gradient centrifugation (Nycoprep
TM 1.077A; Medinor). T cells were
removed using magnetic pan-mouse IgG-coated DynabeadsH
(Invitrogen Dynal, Norway) coated with OX-19 (anti-CD5) and
R73 (anti-ab T cell receptor) mAb. The number of CD3
+ cells was
thus reduced at least fivefold to less than 0.25% of total BM cells (data
not shown). For DLI, LNC (of which approximately 60% were CD3
+
T cells, data not shown) were obtained from mesenteric and cervical
lymph nodes of 10-12 w-old male and female PVG.7B rats by
filtering through cell strainers (BD Biosciences). The CD3
+ Tc e l l
contents of the BM graft and DLI were controlled by flow cytometric
analysis (not shown) after staining with PE-conjugated G4.18 (anti-
CD3; BD Biosciences) mAb.
Male BN rats were transplanted at 9 w of age with 30610
6 T
cell-depleted PVG.7B BM cells by intravenous injection shortly
after receiving 9.0 Gy total body irradiation (GammacellH 3000;
MDS Nordion) under anesthesia. 14 days post transplantation,
GvHD was invoked by DLI of the specified doses of PVG.7B
LNC. MSC were harvested, washed and resuspended in
phosphate buffered saline at a cell density of 1–2610
6 per mL
for injection at the specified time points. Transplanted animals
were frequently and carefully monitored, and were scored weekly
for disease symptoms using a protocol by Cooke et alia [33]. In this
model, cachexia, severe kyphosis, ruffled fur, skin flaking and
lesions and alopecia were predictive of GvHD. Rats suffering from
lethal GvHD were euthanized with CO2 at defined humane end
points (GvHD score exceeding 8; body weight below 150 g).
Donor BM engraftment was evaluated both by clinical observation
(weight gain, anemia) and flow cytometry using HIS41 (anti-rat
CD45) mAb (a kind gift from Jaap Kampinga, Groningen, The
Netherlands) specific for the RT7.2 allele to identify PVG.7B
donor leukocytes. 7 rats (8.9%) of a total of 79 recipients failed to
engraft and were excluded from the analysis.
Statistical analysis
Normal distribution of data was assumed and tested using
Shapiro-Wilk’s test. Student’s t test (paired, two-tailed) was used to
evaluate the probability of differences between samples. For in vivo
experiments, overall survival was compared by the log-rank test and
GvHD scores by Student’s t test (unpaired, two-tailed) for group
differences. Analysis was performed using SPSSH software version
17.0 (SPSS Inc.,IL)with a Pvalue below0.05 deemedassignificant.
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Figure S1 Mycoplasma-infected MSC reduce the num-
bers of T regulatory and live cells in mitogen-stimulated
lymphocyte cultures. Mycoplasma-infected MSC (PVG.7B;
gray bars) were added at the start of a Con A stimulated culture of
PVG.7B LNC at the indicated dilutions (log [MSC:LNC]). The
relative frequency of (A) CD4
+CD25
hiFoxP3
+ T regulatory (Treg)
cells and (B) live cells (propidium iodide
low) were determined by flow
cytometry after 3 d of co-culture. Cell death was increased when
mycoplasma-infected MSC were present. In panel A, the mean
valuesplusthe standard errorof the mean oftriplicates as well asthe
test statisticsforcell frequencies compared tothepositivecontrol are
shown. Data are representative of three independent experiments.
(TIF)
Figure S2 Morphology, differentiation potential and
phenotype of mycoplasma-infected rat BM-derived
MSC. Light microscopy of cell culture, differentiation assays
and flow cytometric staining of MSC infected with M. hyorhinis.( A)
MSC from PVG BM appear as fibroblast-like spindle-shaped cells
that adhere to plastic in vitro (third passage). MSC have the
capacity to differentiate into adipocytes (B) as shown by staining of
neutral lipids in fat vacuoles with Oil Red O and osteocytes (C)b y
staining areas of calcification with Alizarin Red. (D) Surface
expression of CD31 (PECAM-1), CD45 (CLA), CD59 (MAC
inhibitor), CD71 (transferrin receptor), CD90 (Thy-1) and
CXCR4 as well as MHC-I (RT1-A) and MHC-II (RT1-B/D)
on MSC. Histograms show the relative intensity of surface antigen
(solid lines) compared to isotype controls (filled) by flow cytometric
staining. Mycoplasma-infected PVG.1U MSC form adipocytes (E)
and osteocytes (F) under culture conditions inducing differentia-
tion (cf. Materials and Methods) and remain multipotent (G, H)
after clearing the infection with Mynox reagent. (A) Original
magnification 1006,( B, C)4 0 6,( E–H) 2006.
(TIF)
Figure S3 MSC inhibition of MLR is not reversed by
addition of exogenous IFNc nor by anti-IL-6 antibody. (A)
A panel of cytokines was measured in the medium supernatant of a
confluent culture of infected MSC (PVG) 20–24 h after medium
was replaced. MSC constitutively secrete IL-6, while other
cytokines were not detectable. (B) Inhibition of proliferation in
allogeneic MLR at 1:1000 MSC:LNC ratio could not be reverted
by addition of anti-rat IL-6 mAb (aIL-6; 2 mgm L
21) or recom-
binant rat IFNc (500 U mL
21) at the start of co-culture.
Representative data from two independent experiments are shown
as mean values plus one standard error of the mean of (A) triplicate
and (B) quadruplicates tests.
(TIF)
Figure S4 Rats suffering from GvHD are not rescued by
repeated injections of mycoplasma-infected MSC. MSC
from two different cell lines subsequently found to be infected with
M. hyorhinis were injected in rats suffering from experimental acute
GvHD. Irradiated BN recipients were transplanted with
30610
6 T cell-depleted donor PVG.7B BM cells (n) and received
a DLI 14 d later (m) of graded doses of either (A, B) 2.5610
6 or
(C, D) 1.5610
6 donor PVG.7B LNC. Two rats that received BM
cells only (no DLI) and did not develop GvHD are also shown in
panel C. 0.5–1610
6 MSC from PVG.1U (A, B) or 1–2610
6 MSC
from PVG (C, D) were injected either repeatedly on 0, 7, and 14 d
(bold line, 36MSC) or once on 14 d (solid line, 16MSC) after
DLI. Control rats received no MSC (dashed line, no MSC). (A, C)
Cumulative survival is depicted as Kaplan-Meier plots. (B, D)
GvHD symptoms, including relative change in body weight, were
assigned discrete values using a semi-quantitative scoring table
adapted from Cooke et alia [33]. GvHD scores are shown together
with the median (horizontal line) at 7 d and 14 d after DLI,
respectively. The respective MSC treatment protocols had no
statistically significant effect on overall survival nor the GvHD
score of rats treated with 36MSC (N)o r1 6MSC (N) compared
to the controls (u). Data were pooled from (A, B) two and (C, D)
four individual experiments.
(TIF)
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